Effectiveness and tolerability of treatment for isolated actinic keratoses: A retrospective comparison between cryotherapy, CO2 laser and 5-fluorouracil 0.5%/salicylic acid 10
- PMID: 33528869
- DOI: 10.1111/dth.14846
Effectiveness and tolerability of treatment for isolated actinic keratoses: A retrospective comparison between cryotherapy, CO2 laser and 5-fluorouracil 0.5%/salicylic acid 10
Abstract
Actinic keratoses (AK) have been described as either intraepithelial keratinocytic dysplasia that can evolve into invasive squamous cell carcinoma (SCC) or as in situ SCC that can progress into an invasive form. A retrospective study was conducted to compare outcomes of three different topical therapies for patients with single AK (<4): cryotherapy, CO2 laser and 5-fluorouracil 0.5%/salicylic acid 10%. We included 72 patients who presented at the Dermatology Clinic of Maggiore Hospital of Trieste between 1 November 2019 and 31 January 2020 for the treatment of AKs. All treatments led to a significant reduction in the average diameter of AK. Pain felt by patients was significantly lower after 5-FU 0.5%/SA 10%. Side effects appeared similarly distributed among the three groups, with erythema and crusts being the most frequent. Aesthetic outcomes were highest in the 5-FU 5%/SA 10% group, as evaluated by both the patient and the operator. Cryotherapy, CO2 laser and 5-FU 5%/SA 10% were all effective, with no significant efficacy differences among them. Additionally, 5-FU 5%/SA 10% was proved to have the best aesthetic result and to cause the least pain, while necessitating long-term administration. This should be taken into account for patients with low pain tolerance and low treatment adherence. Cryotherapy and CO2 laser have the advantage of requiring a single session, which might be more suitable for uncooperative patients.
Keywords: 5-fluorouracil; CO2 laser; actinic keratoses; cryotherapy; salicylic acid; treatment.
© 2021 Wiley Periodicals LLC.
References
REFERENCES
-
- Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis-International League of Dermatological Societies in cooperation with the European Dermatology Forum-Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069-2079. https://doi.org/10.1111/jdv.13180.
-
- Conforti C, Giuffrida R, Pizzichetta MA, Di Meo N, Magaton-Rizzi G, Zalaudek I. Integrating the concept of field cancerization in the classification and risk assessment of cutaneous squamous cell carcinoma: proposal for a new classification and terminology of keratinocyte skin cancer. J Eur Acad Dermatol Venereol. 2019;33(9):e327-e330. https://doi.org/10.1111/jdv.15624.
-
- Martin GM. Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations. J Dermatolog Treat. 2011;22(5):288-297. https://doi.org/10.3109/09546631003797072.
-
- Stockfleth E. From a new vision of actinic keratosis to imiquimod 3.75%, the new treatment standard. Introduction. J Eur Acad Dermatol Venereol. 2015;29(suppl 1):1-2. https://doi.org/10.1111/jdv.12827.
-
- Conforti C, Beninati E, Dianzani C. Are actinic keratoses really squamous cell cancer? How do we know if they would become malignant? Clin Dermatol. 2018;36(3):430-432. https://doi.org/10.1016/j.clindermatol.2017.08.013.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials

